Datwyler starts elastomer component supply for GLP-1 therapy

Altdorf, Switzerland – Datwyler has started serial production and supply of elastomer components for prefilled syringes used in glucagon-like peptide-1 (GLP-1) receptor agonist therapies, the Swiss group said 2 April.

GLP-1 receptor agonist therapies are a rapidly growing class of injectable medications used primarily to treat type 2 diabetes and, more recently, obesity.

According to Datwyler, they represent “one of the fastest-growing segments in the injectable drug market.”

Having undergone “development and validation milestones,” the components, which include plungers for prefilled syringes, are manufactured under Datwyler's FirstLine production standard and will be integrated into an injection device for a GLP-1 drug.

Datwyler stated that it was committed to “a consistent and scalable increase in delivery volume.”

The Swiss group is “actively engaged with a broad network of current and prospective partners, supporting the advancement and commercialisation of innovative GLP-1 therapies.”

The commercial supply of the components follows Datwyler’s long-term investment in its global manufacturing footprint and portfolio diversification, which it says has positioned it as “a preferred partner for globally leading pharmaceutical companies.”

Datwyler expects to benefit from “continued market expansion,” as GLP-1 therapies are seen as a major mid-term growth opportunity.

“The segment is characterised by high entry barriers and substantial unmet medical needs,” the Swiss group said.

These factors, it said, enhance Datwyler's value as a "reliable, high-performance component supplier."